Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Continues Looking For The “Right” Biotech Buying Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.

You may also be interested in...

Merck’s Clark: 2009 is a Year of Fundamental Change

In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Can Big Pharma Save Biotech Investors?

Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts